Form 8-K - Current report:
SEC Accession No. 0001493152-25-004880
Filing Date
2025-02-04
Accepted
2025-02-04 17:29:33
Documents
14
Period of Report
2025-02-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40997
2 ex10-1.htm EX-10.1 120771
  Complete submission text file 0001493152-25-004880.txt   359160

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ensc-20250204.xsd EX-101.SCH 3012
4 XBRL LABEL FILE ensc-20250204_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ensc-20250204_pre.xml EX-101.PRE 22357
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3741
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

EIN.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 25589742
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)